IMCD's Inflection: From Green Shoots to a Promising Start
After a year of demand softness, IMCD's Q2 acceleration and supplier wins signal a turning point.
IMCD.AS · Earnings Call · 2026-07-29
From Softness to Inflection
In its 2026 half-year results, IMCD reported a striking sequential turnaround. Organic gross profit swung from -4% in Q1 to +7% in Q2, and organic EBITA from -9% to +11%, with all regions contributing to the second-quarter growth. CEO Marcus Jordan credited a combination of pricing tailwinds, market share gains, and strong commercial execution. As he put it, “I'm proud of how our teams navigated the dynamic environment, which included the majority of our suppliers implementing price increases.” — Marcus Jordan, Chief Executive Officer · 2026-07-29 The magnitude of these price increases was concentrated in the smaller semi-specialty part of the portfolio, but the company was careful to pass them on responsibly, focusing on long-term customer relationships. This inflection is visible in the company's own keyword trajectory: promising start vaulted to the top spot for Q2 2026, a phrase Marcus used explicitly when discussing early Q3 demand. Similarly, supplier win appears as a key driver for the first time, reflecting a deliberate push to convert new mandates. These are not just buzzwords — they mark a departure from the defensive tone of the past year.Supplier Wins: A New Growth Engine
A central theme in the call was the success in winning new suppliers, which management attributed to both market conditions and internal investments. Marcus noted, “I think this is the first time that we've spoken proactively about the wins. So it's with great pleasure and a credit to the whole team that we've really been able to convert those or some of those.” — Marcus Jordan, Chief Executive Officer · 2026-07-29 He linked this to a doubling down on the sales organization during a difficult climate, and to suppliers themselves reevaluating their outsourced distribution needs. The wins are broad-based, not limited to one market, and are already contributing to organic growth — a key reason the Q2 rebound feels more durable. This represents a clear shift from prior quarters, where the conversation was dominated by competitive pressure from Asia and pricing weakness in semi-specialties. In fact, the keyword semi specialty — which had been a top concern — now appears as a source of pricing tailwinds, albeit with the caveat that increases were smaller in the larger specialty component.Contrast with Prior Tone
The contrast with earlier calls is stark. In February 2026, Marcus described demand as still muted: “with very muted demand in general. Just-in-time deliveries have pretty much, as we said before, become the norm.” — Marcus Jordan · 2026-02-18 He also said they did not yet see green shoots. By July, those green shoots have evidently materialized, and the keyword green shoots actually dropped sharply from the company's vocabulary — replaced by concrete evidence of improvement. Similarly, the prior Q&A repeatedly discussed Chinese competition and price pressure on the semi-specialty side. This quarter, Marcus acknowledged that while some of that pressure remains, the dynamic has shifted: “it's fair to say that in some of the more remote countries like Brazil, we did see less competition on the semi-specialty side during the second quarter.” — Marcus Jordan, Chief Executive Officer · 2026-07-29 This is a genuine reversal of the narrative that has weighed on the stock for over a year.What It Means
IMCD's report is a company-specific signal, not a broad market theme. The global keyword trajectory for 2026Q3 is dominated by unrelated topics like “Batch Zero” and “Earnings growth,” and recent reporters in chemicals have not echoed this specific turnaround. But for IMCD, the combination of a strong Q2, a promising Q3 start, and a healthy pipeline of supplier wins suggests the business is entering a more constructive phase. The balance sheet remains a source of flexibility: net debt is stable, leverage is low, and free cash flow conversion improved to 76.2%, giving management ample room to resume M&A when opportunities arise. As Marcus said,For investors, the key takeaway is that IMCD may have turned the corner. The shift from defensive language to offensive execution, backed by tangible supplier wins and a favorable pricing environment, justifies a re-rating of expectations. Whether this proves to be a cyclical rebound or a structural improvement in the company's growth profile, the evidence from the call tilts positive.we focus on the things that we can control and are committed to delivering long-term growth for our partners and stakeholders in the years ahead.